Geron Corporation Scientists and Collaborators Demonstrate TAT2 - A Small Molecule Telomerase Activator - Enhances Antiviral Function of Immune Cells From HIV+ Donors

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data on TAT2, a small molecule telomerase activator. The studies show that human CD8+ T-cells from HIV-infected donors exposed to TAT2 exhibited increased telomerase activity, resulting in retardation of telomere shortening, an increase in T-cell proliferation, and enhancement of critical antiviral functions against HIV-1.

Back to news